158 results on '"Rauber C"'
Search Results
2. Planar Shape Databases with Affine Invariant Search
- Author
-
Startchik, S., primary, Milanese, R., additional, Rauber, C., additional, and Pun, T., additional
- Published
- 1998
- Full Text
- View/download PDF
3. Electroconvulsive Therapy as a Potential Trigger of Adult Onset Still’s Disease
- Author
-
Blank N, Merle U, Rauber C, and Ruping Fm
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,Pediatrics ,Anakinra ,business.industry ,medicine.medical_treatment ,Hepatosplenomegaly ,Aseptic meningitis ,medicine.disease ,Surgery ,Electroconvulsive therapy ,Macrophage activation syndrome ,Etiology ,Medicine ,medicine.symptom ,Complication ,business ,Depression (differential diagnoses) ,medicine.drug - Abstract
Introduction: Adult onset Still’s disease (AOSD) is an inflammatory disorder of unknown etiology. Macrophage activation syndrome (MAS) is a complication of AOSD and may present with multiorgan failure including cerebral involvement. Clinical presentation: We describe a 43-year-old female patient with major depression treated with electroconvulsive therapy (ECT). She presented with febrile pharyngitis, arthralgia, rashes, lymphadenopathy, hepatosplenomegaly, liver failure and aseptic meningitis. Elevated serum ferritin and negative blood cultures were consistent with the diagnosis of AOSD complicated by MAS. The patient was treated with corticosteroids and anakinra and recovered rapidly. Conclusion: The case highlights aseptic meningitis, depression and multiorgan failure as a feature of AOSD/ MAS possibly triggered by ECT. Anakinra is an effective treatment in severe MAS.
- Published
- 2017
- Full Text
- View/download PDF
4. Herpesviruses in bile: increasing sensitivity by testing the right compartment
- Author
-
Rauber, C., primary, Bartelheimer, K., additional, and Gotthardt, D., additional
- Published
- 2017
- Full Text
- View/download PDF
5. Hypercalcemia, necrotizing pancreatitis and bone lesions: a benign cause
- Author
-
Rauber, C, primary
- Published
- 2017
- Full Text
- View/download PDF
6. The Combination of Ionizing Radiation and Toll-Like Receptor 7/8 Agonists Creates Local and Abscopal Tumor Immune Responses In Vivo
- Author
-
Nicolay, N.H., primary, Schölch, S., additional, Rauber, C., additional, Lopez Perez, R., additional, Debus, J., additional, and Huber, P.E., additional
- Published
- 2016
- Full Text
- View/download PDF
7. Improved survival in patients with primary sclerosing cholangitis and normalization of serum cholestasis markers after biliary dilatation therapy
- Author
-
Rupp, C, primary, Friedrich, K, additional, Wannhoff, A, additional, Rauber, C, additional, Weiss, KH, additional, Stremmel, W, additional, Sauer, P, additional, and Gotthardt, DN, additional
- Published
- 2015
- Full Text
- View/download PDF
8. Veränderungen des immunologischen Status bei Patienten mit „late-onset“-Primär Sklerosierender Cholangitis (PSC)
- Author
-
Rupp, C, primary, Rössler, A, additional, Zhou, T, additional, Rauber, C, additional, Sun, LA, additional, Friedrich, K, additional, Wannhoff, A, additional, Weiss, K, additional, Sauer, P, additional, Süsal, C, additional, Stremmel, W, additional, and Gotthardt, D, additional
- Published
- 2015
- Full Text
- View/download PDF
9. Sampling strategies and on-site analytical techniques: detailed comparison on a former coal carbonisation site
- Author
-
DUBOURGUIER, H.C., Desreumaux, L., Le François, A., Cazier, F., Paluel,, Rauber, C., Accart, G., ProdInra, Migration, Département Caractérisation et Elaboration des Produits Issus de l'Agriculture (CEPIA), and Institut National de la Recherche Agronomique (INRA)
- Subjects
[SPI.GPROC] Engineering Sciences [physics]/Chemical and Process Engineering ,[SDV.IDA]Life Sciences [q-bio]/Food engineering ,PROFIL DU SOL ,[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineering ,[SDV.IDA] Life Sciences [q-bio]/Food engineering - Published
- 1998
10. TAT hitchhiker selection expanded to folding helpers, multimeric interactions and combinations with protein fragment complementation
- Author
-
Speck, J., primary, Rauber, C., additional, Kukenshoner, T., additional, Niemoller, C., additional, Mueller, K. J., additional, Schleberger, P., additional, Dondapati, P., additional, Hecky, J., additional, Arndt, K. M., additional, and Muller, K. M., additional
- Published
- 2012
- Full Text
- View/download PDF
11. A Geotechnical Investigation of Rock-Like Material Lining Joints in Shale Bedrock
- Author
-
RAUBER, C. C, primary and SHAKOOR, A., additional
- Published
- 2009
- Full Text
- View/download PDF
12. Herstellung Von Partikelverstärkten Verbundwerkstoffen Durch Magnesiumspritzgießen
- Author
-
Rauber, C., primary, Lohmüller, A., additional, Hilbinger, M., additional, Opel, S., additional, Hartmann, M., additional, and Singer, R.F., additional
- Published
- 2009
- Full Text
- View/download PDF
13. De-capitating managed-care contracts: some providers say global capitation has tied a noose around their finances.
- Author
-
Rauber C
- Published
- 1999
14. Disease management can be good for what ails patients and insurers: health plans are using venders and internal programs to get results in treating chronic conditions.
- Author
-
Rauber C
- Published
- 1999
15. John Victor, Computer Educator
- Author
-
Rauber, C.
- Subjects
Biography ,Educational Software ,Companies ,Marketing Strategy ,Computer-Assisted Instruction ,Home Computers ,Chief Executive Officers ,Computer Software Industry - Published
- 1984
16. Influence of internal imperfections on the fatigue resistance of cast steel – testing methodology
- Author
-
Nagel Sven, Rauber Christof, Veile Ines, Knödel Peter, and Ummenhofer Thomas
- Subjects
Engineering (General). Civil engineering (General) ,TA1-2040 - Abstract
Tensile fatigue specimen of G20Mn5 and G22NiMoCr5-6 were tested to quantify the influence of internal defects on the fatigue resistance of cast steel components. Defects with varying sizes, geometric shapes and distribution were enforced by influencing the solidification and recorded by computer tomography (CT). Besides the characteristics of the detected cavities, the surrounding fungoid microstructure is classified and evaluated. Later the specimens were tested under cyclic tension and S/N-curves are derived. These data form the basis for extensive numerical simulations of the damage process and the crack growth of every individual specimen. Both processes are affected by the local multiaxial stress states and have their origin in the inside of the specimen. For validation, knowledge of the crack initiation time and propagation properties are essential. Therefore, all specimens respectively the properties of the internal defects are monitored during testing with three different state-of-the-art non-destructive testing (NDT) methods. Background and application of these NDT techniques are described within this paper. Finally, fracture surface analyses show different failure modes and provide further information for model validation.
- Published
- 2019
- Full Text
- View/download PDF
17. HMO: open to alternatives.
- Author
-
Rauber C
- Published
- 1998
18. Les écoles et classes ménagères en Belgique
- Author
-
Rauber, C.
- Abstract
Rauber C. Les écoles et classes ménagères en Belgique. In: La revue pédagogique, tome 24, Janvier-Juin 1894. pp. 333-347.
- Published
- 1894
19. Les écoles professionnelles pour les jeunes filles, en Belgique
- Author
-
Rauber, C.
- Abstract
Rauber C. Les écoles professionnelles pour les jeunes filles, en Belgique. In: La revue pédagogique, tome 24, Janvier-Juin 1894. pp. 154-163.
- Published
- 1894
20. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors
- Author
-
Schölch S, Rauber C, Tietz A, Nn, Rahbari, Bork U, Thomas Schmidt, Kahlert C, Haberkorn U, Ma, Tomai, Ke, Lipson, Carretero R, Weitz J, Koch M, and Pe, Huber
21. Photojournal: NASA's Image Access Home Page.
- Author
-
Rauber, C. M.
- Subjects
JET propulsion ,PHOTOJOURNALISM ,COMPUTER network resources - Abstract
The article reviews the web site of the Photojournal of the Jet Propulsion Laboratory of the U.S. National Aeronautics & Space Administration (NASA), located at http://photojournal.jpl.nasa.gov/.
- Published
- 2014
- Full Text
- View/download PDF
22. The Feynman Lectures on Physics.
- Author
-
Rauber, C. M.
- Subjects
PHYSICS websites ,LECTURES & lecturing ,COMPUTER network resources - Abstract
The article reviews the website the Feynman Lectures on Physics, found at http://www.feynmanlectures.info/.
- Published
- 2013
- Full Text
- View/download PDF
23. SpaceRef.
- Author
-
Rauber, C. M.
- Subjects
OUTER space ,COMPUTER network resources - Abstract
The article reviews the web site SpaceRef, located at http://www.spaceref.com/, from the SpaceRef media company.
- Published
- 2013
- Full Text
- View/download PDF
24. Archival and retrieval of historical watermark images.
- Author
-
Rauber, C., Tschudin, P., Startchik, S., and Pun, T.
- Published
- 1996
- Full Text
- View/download PDF
25. Extending the ADA to HIV: high court rules afflicted workers are covered by act.
- Author
-
Rauber C
- Published
- 1998
26. Making a recovery.
- Author
-
Rauber C
- Published
- 1999
27. Employers may take more hits.
- Author
-
Rauber C
- Published
- 1999
28. Judge: Doc's lawsuit can proceed.
- Author
-
Rauber C
- Published
- 1999
29. HIV treatment data soon to be on Web.
- Author
-
Rauber C
- Published
- 1999
30. Market deflates for provider-owned HMOS.
- Author
-
Rauber C
- Published
- 1999
31. PPOs riding a wave of popularity.
- Author
-
Rauber C
- Published
- 1999
32. Premium jumps boost managed-care giants.
- Author
-
Rauber C
- Published
- 1999
33. Study: Capitated risk not always understood.
- Author
-
Rauber C
- Published
- 1999
34. Information, please.
- Author
-
Rauber C
- Published
- 1999
35. Kaiser losses mount.
- Author
-
Rauber C
- Published
- 1998
36. HMO study finds $768 million loss.
- Author
-
Rauber C
- Published
- 1998
37. Survey: Providers exiting insurance.
- Author
-
Rauber C
- Published
- 1998
38. Singing the blues.
- Author
-
Rauber C
- Published
- 1998
39. Stamping through astronomy.
- Author
-
Rauber, C. M.
- Subjects
STAMP collections ,ASTRONOMY ,NONFICTION - Published
- 2014
- Full Text
- View/download PDF
40. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
- Author
-
Carolina Alves Costa Silva, Deborah Lefevre, Lisa Derosa, Claudia Grajeda-Iglesias, Gladys Ferrere, Maryam Tidjani Alou, Anne-Gaëlle Goubet, Fanny Aprahamian, Conrad Rauber, Didier Raoult, Aurélie Fluckiger, Monica Arnedos, Damien Drubay, Romain Daillère, Cassandra Thelemaque, Tim D. Spector, Sylvère Durand, Liwei Zhao, Guido Kroemer, Emeline Colomba, Oliver Kepp, Valerio Iebba, Laurence Zitvogel, Nicola Segata, Francesco Asnicar, Marine Fidelle, Peng Liu, Bernhard Ryffel, Immunologie intégrative des tumeurs et immunothérapie des cancers (INTIM), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Università degli studi di Trieste = University of Trieste, Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS), Institut Gustave Roussy (IGR), Oncologie gynécologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Pathologie mammaire, Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Centre for Integrative Biology (CIBIO), University of Trento (CIBIO), University of Trento [Trento], King‘s College London, Centre d'Investigation Clinique en Biotherapie des cancers (CIC 1428 , CBT 507 ), Institut Gustave Roussy (IGR)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), ANR-16-RHUS-0008,LUMIERE,LUMIERE(2016), European Project: 825410,ONCOBIOME, Ferrere, G., Alou, M. T., Liu, P., Goubet, A. -G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., Daillere, R., Thelemaque, C., Grajeda-Iglesias, C., Silva, C. A. C., Aprahamian, F., Lefevre, D., Zhao, L., Ryffel, B., Colomba, E., Arnedos, M., Drubay, D., Rauber, C., Raoult, D., Asnicar, F., Spector, T., Segata, N., Derosa, L., Kroemer, G., Zitvogel, L., Gestionnaire, Hal Sorbonne Université, LUMIERE - - LUMIERE2016 - ANR-16-RHUS-0008 - RHUS - VALID, European Union’s Horizon 2020 research and innovation programme under grant agreement. - ONCOBIOME - 825410 - INCOMING, École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), University of Trieste, Centre National de la Recherche Scientifique (CNRS)-Université d'Orléans (UO), and Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
0301 basic medicine ,Ketogenic ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,Cancer ,Immunotherapy ,Metabolism ,Mouse models ,Oncology ,3-Hydroxybutyric Acid ,Animals ,CTLA-4 Antigen ,Cell Line, Tumor ,Combined Modality Therapy ,Female ,Gastrointestinal Microbiome ,Humans ,Immune Checkpoint Inhibitors ,Ketone Bodies ,Kidney Neoplasms ,Melanoma, Experimental ,Mice ,Mice, Inbred BALB C ,Mice, Inbred C57BL ,Neoplasms, Experimental ,Receptors, G-Protein-Coupled ,Diet, Ketogenic ,Pharmacology ,CXCR3 ,Inbred C57BL ,0302 clinical medicine ,Neoplasms ,Ketogenesis ,Receptors ,Ketone Bodie ,Melanoma ,Inbred BALB C ,Tumor ,Chemistry ,Kidney Neoplasm ,General Medicine ,3. Good health ,[SDV] Life Sciences [q-bio] ,Immunosurveillance ,030220 oncology & carcinogenesis ,Ketone bodies ,Medicine ,Human ,Research Article ,Immune Checkpoint Inhibitor ,Mouse model ,Cell Line ,03 medical and health sciences ,Experimental ,G-Protein-Coupled ,Downregulation and upregulation ,medicine ,Animal ,Immune checkpoint ,Diet ,030104 developmental biology ,Ketogenic diet - Abstract
International audience; Limited experimental evidence bridges nutrition and cancer immunosurveillance. Here, we show that ketogenic diet (KD) - or its principal ketone body, 3-hydroxybutyrate (3HB), most specifically in intermittent scheduling - induced T cell-dependent tumor growth retardation of aggressive tumor models. In conditions in which anti-PD-1 alone or in combination with anti-CTLA-4 failed to reduce tumor growth in mice receiving a standard diet, KD, or oral supplementation of 3HB reestablished therapeutic responses. Supplementation of KD with sucrose (which breaks ketogenesis, abolishing 3HB production) or with a pharmacological antagonist of the 3HB receptor GPR109A abolished the antitumor effects. Mechanistically, 3HB prevented the immune checkpoint blockade-linked upregulation of PD-L1 on myeloid cells, while favoring the expansion of CXCR3+ T cells. KD induced compositional changes of the gut microbiota, with distinct species such as Eisenbergiella massiliensis commonly emerging in mice and humans subjected to carbohydrate-low diet interventions and highly correlating with serum concentrations of 3HB. Altogether, these results demonstrate that KD induces a 3HB-mediated antineoplastic effect that relies on T cell-mediated cancer immunosurveillance.
- Published
- 2021
- Full Text
- View/download PDF
41. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients
- Author
-
Conrad Rauber, Gladys Ferrere, Jean-Eudes Fahrner, Valerio Iebba, Nicolas Pons, Romain Daillère, Emmanuelle Le Chatellier, Hugo Roume, Filippo Pietrantonio, Nicola Segata, Marine Fidelle, Anne-Gaëlle Goubet, Carolina Alves Costa Silva, Bertrand Routy, Connie P.M. Duong, Karim Fizazi, Edoardo Pasolli, Safae Terrisse, Beatrice Casu, Laurence Albiges, Bernard Escudier, Mélodie Bonvalet, Maryam Tidjani Alou, Laurie Alla, Kristina Iribarren, Didier Raoult, Aude Desnoyer, Guido Kroemer, Lisa Derosa, Laura Mondragón, Nathalie Galleron, Anna Reni, Fabien Lemaitre, Laurence Zitvogel, Derosa, L., Routy, B., Fidelle, M., Iebba, V., Alla, L., Pasolli, E., Segata, N., Desnoyer, A., Pietrantonio, F., Ferrere, G., Fahrner, J. -E., Le Chatellier, E., Pons, N., Galleron, N., Roume, H., Duong, C. P. M., Mondragon, L., Iribarren, K., Bonvalet, M., Terrisse, S., Rauber, C., Goubet, A. -G., Daillere, R., Lemaitre, F., Reni, A., Casu, B., Alou, M. T., Alves Costa Silva, C., Raoult, D., Fizazi, K., Escudier, B., Kroemer, G., Albiges, L., Zitvogel, L., Immunologie anti-tumorale et immunothérapie des cancers (ITIC), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Faculté de médecine de l'Université Paris-Sud [Kremlin Bicêtre, Paris], Université Paris-Saclay, Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), MetaGenoPolis (MGP (US 1367)), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), University of Naples Federico II = Università degli studi di Napoli Federico II, Centre for Integrative Biology (CIBIO), University of Trento (CIBIO), University of Trento [Trento], Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Gustave Roussy (IGR), IRCCS Istituto Nazionale dei Tumori [Milano], Université Paris-Sud - Paris 11 (UP11), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Suzhou Institute of Systems Medicine [Jiangsu, P.R. China], Karolinska University Hospital [Stockholm], Philanthropia Foundation ESMO translational research fellowship Fonds de la Recherche en Sante du Quebec Kidney Cancer Research Network of Canada Ligue nationale contre le cancerFrench National Research Agency (ANR)French National Research Agency (ANR)ERA-Net for Research on Rare Diseases Fondation ARC pour la Recherche sur le CancerRegion Ile-de-France Fondation de FranceFondation pour la Recherche MedicaleEuropean Commission Joint Research CentreEuropean Research Council (ERC)Fondation Carrefour, High-end Foreign Expert Program in China GDW20171100085 GDW20181100051Institut National du Cancer (INCA) FranceInserm (HTE) Institut Universitaire de France Leducq FoundationSearave and Carrefour Foundation SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE 2.0) BMS Foundation SIRIC Cancer Research and Personalized Medicine (CARPEM) Paris Alliance of Cancer Research Institutes (PACRI) Mediterranee Infection 10-IAHU-03Region Provence-Alpes-Cote d'AzurNational Research, Development and Innovation Fund of Hungary FIEK_16-1-20160005Research and Technology Innovation Fund NAP2-2017-1.2.1-NKP-0002Breast Cancer Research Foundation BCRF-17-156Novo Nordisk Foundation Interdisciplinary Synergy Program Grant NNF15OC0016584, ANR-16-RHUS-0008,LUMIERE,LUMIERE(2016), European Project: 825410,ONCOBIOME, University of Naples Federico II, Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Gustave Roussy Cancer Campus (GRCC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Saclay, Université Paris-Sud [Le Kremlin-Bicêtre] (Faculté de Médecine), Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM), Centre d’Investigation Clinique en Biothérapies [CHU Pitié-Salpêtrière] (CIC-BT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Université Paris-Saclay, Faculté de Pharmacie, 92290 Châtenay-Malabry, France, MetaGenoPolis, European Institute of Oncology [Milan] (ESMO), Gustave Roussy Cancer Campus, Partenaires INRAE, Chinese Academy of Medical Sciences, Philanthropia Foundation ESMO translational research fellowship.Fonds de la Recherche en Sante du Quebec Kidney Cancer Research Network of CanadaLigue nationale contre le cancerFrench National Research Agency (ANR) ERA-Net for Research on Rare DiseasesFondation ARC pour la Recherche sur le CancerRegion Ile-de-FranceFondation de FranceFondation pour la Recherche MedicaleEuropean Commission Joint ResearchCentre European Research Council (ERC)Fondation Carrefour, and High-end Foreign Expert Program in China GDW20171100085 GDW20181100051Institut National du Cancer (INCA) France Inserm (HTE) Institut Universitaire de FranceLeducq FoundationSearave and Carrefour Foundation SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE 2.0) BMS Foundation SIRIC Cancer Research and Personalized Medicine (CARPEM) Paris Alliance of Cancer Research Institutes (PACRI)Mediterranee Infection 10-IAHU-03Region Provence-Alpes-Cote d'AzurNational Research, Development and Innovation Fund of Hungary FIEK_16-1-20160005Research and Technology Innovation Fund NAP2-2017-1.2.1-NKP-0002Breast Cancer Research Foundation BCRF-17-156Novo Nordisk Foundation Interdisciplinary Synergy Program Grant NNF15OC0016584
- Subjects
Oncology ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,Antibiotics ,030232 urology & nephrology ,Tyrosine kinase inhibitor ,Immune checkpoint inhibitor ,Tyrosine-kinase inhibitor ,Feces ,Mice ,0302 clinical medicine ,Cancer immunotherapy ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Renal cell carcinoma ,Prospective Studies ,Immune Checkpoint Inhibitors ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Microbiota ,Kidney cancer ,Kidney Neoplasms ,3. Good health ,Nivolumab ,030220 oncology & carcinogenesis ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,medicine.medical_specialty ,medicine.drug_class ,Urology ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Predictive Value of Tests ,Internal medicine ,medicine ,Animals ,Humans ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,Carcinoma, Renal Cell ,[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health ,business.industry ,Antibiotic ,Immunotherapy ,medicine.disease ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,Immune checkpoint ,Gastrointestinal Microbiome ,Drug Resistance, Neoplasm ,business - Abstract
Background: The development of immune checkpoint blockade (ICB) has revolutionized the clinical outcome of renal cell carcinoma (RCC). Nevertheless, improvement of durability and prediction of responses remain unmet medical needs. While it has been recognized that antibiotics (ATBs) decrease the clinical activity of ICB across various malignancies, little is known about the direct impact of distinct intestinal nonpathogenic bacteria (commensals) on therapeutic outcomes of ICB in RCC. Objective: To evaluate the predictive value of stool bacteria composition for ICB efficacy in a cohort of advanced RCC patients. Design, setting, and participants: We prospectively collected fecal samples from 69 advanced RCC patients treated with nivolumab and enrolled in the GETUG-AFU 26 NIVOREN microbiota translational substudy phase 2 trial (NCT03013335) at Gustave Roussy. We recorded patient characteristics including ATB use, prior systemic therapies, and response criteria. We analyzed 2994 samples of feces from healthy volunteers (HVs). In parallel, preclinical studies performed in RCC-bearing mice that received fecal transplant (FMT) from RCC patients resistant to ICB (NR-FMT) allowed us to draw a cause-effect relationship between gut bacteria composition and clinical outcomes for ICB. The influence of tyrosine kinase inhibitors (TKIs) taken before starting nivolumab on the microbiota composition has also been assessed. Outcome measurements and statistical analysis: Metagenomic data (MG) from whole genome sequencing (WGS) were analyzed by multivariate and pairwise comparisons/fold ratio to identify bacterial fingerprints related to ATB or prior TKI exposure and patients’ therapeutic response (overall response and progression-free survival), and compared with the data from cancer-free donors. Results and limitations: Recent ATB use (n = 11; 16%) reduced objective response rates (from 28% to 9%, p < 0.03) and markedly affected the composition of the microbiota, facilitating the dominance of distinct species such as Clostridium hathewayi, which were also preferentially over-represented in stools from RCC patients compared with HVs. Importantly, TKIs taken prior to nivolumab had implications in shifting the microbiota composition. To establish a cause-effect relationship between gut bacteria composition and ICB efficacy, NR-FMT mice were successfully compensated with either FMT from responding RCC patients or beneficial commensals identified by WGS-MG (Akkermansia muciniphila and Bacteroides salyersiae). Conclusions: The composition of the microbiota is influenced by TKIs and ATBs, and impacts the success of immunotherapy. Future studies will help sharpen the role of these specific bacteria and their potential as new biomarkers. Patient summary: We used quantitative shotgun DNA sequencing of fecal microbes as well as preclinical models of fecal or bacterial transfer to study the association between stool composition and (pre)clinical outcome to immune checkpoint blockade. Novel insights into the pathophysiological relevance of intestinal dysbiosis in the prognosis of kidney cancer may lead to innovative therapeutic solutions, such as supplementation with probiotics to prevent primary resistance to therapy. Antibiotics prior to immune checkpoint inhibitors have a deleterious clinical impact, reduce the microbiome diversity, and increase Clostridium hathewayi bacteria associated with resistance. Higher baseline microbiome diversity and Akkermansia muciniphila are associated with longer progression-free survival. In murine fecal microbiome transplantation experiments, A. muciniphila can restore the anticancer activity of the combination of anti–PD-1 and CTLA-4.
- Published
- 2020
- Full Text
- View/download PDF
42. Exacerbation of Myopathy in Glycogen Debrancher Deficiency After Liver Transplantation: Case Report and Review of the Literature.
- Author
-
Rauber C, Pfeiffenberger J, Mehrabi A, Mieth M, Zizer E, and Merle U
- Subjects
- Humans, Male, Adult, Glycogen Storage Disease Type III genetics, Glycogen Storage Disease Type III surgery, Liver Transplantation, Muscular Diseases etiology
- Abstract
Background: Glycogen storage disorder (GSD) type IIIa is a rare inherited genetic disorder affecting liver and muscle tissue. Liver transplantation (LT) improves metabolic control, but muscle involvement persists., Case: We report the case of a 31-year-old man who underwent orthotopic LT for end-stage liver disease caused by GSD type IIIa. After LT, he developed worsening clinical signs of myopathy, along with exponentially increasing levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and creatine kinase. Liver-related elevations of AST and ALT were excluded through liver biopsy and endoscopic cholangiography; consequently, AST and ALT elevations were attributed to the underlying muscle involvement. Exacerbation of muscle disease after LT could be attributed to restoration of liver glycogen metabolism after LT, leading to increased glucose accumulation in muscle cells, where the gene defect persists. A dietary intervention with a high-protein, ketogenic diet was initiated but did not lead to significant improvement of myalgia., Conclusion: LT exacerbated muscle disease in a patient with GSD type IIIa. Patients should be counseled about this possible side effect of LT in GSD type IIIa., Competing Interests: Declaration of competing interest CR reports were provided by University Hospital Heidelberg. All the other authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.
- Author
-
Olkus A, Tomczak A, Berger AK, Rauber C, Puchas P, Wehling C, Longerich T, Mehrabi A, Chang DH, Liermann J, Schäfer S, Pfeiffenberger J, Jäger D, Michl P, Springfeld C, and Dill MT
- Subjects
- Humans, Gemcitabine, Cisplatin pharmacology, Cisplatin therapeutic use, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols adverse effects, Deoxycytidine adverse effects, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms etiology, Bile Duct Neoplasms, Antibodies, Monoclonal
- Abstract
Background: The combination of gemcitabine and cisplatin (gem/cis) with the anti-PD-L1-antibody durvalumab was recently approved as first line therapy for biliary tract cancer (BTC) based on the results of the TOPAZ-1 trial., Objective: We aim to analyse the feasibility and efficacy of the triple combination therapy in patients with BTC in a real-world setting and in correspondence with the genetic alterations of the cancer., Methods: In this single-centre retrospective analysis, all patients with BTC and treated with durvalumab plus gem/cis from April 2022 to September 2023 were included. Survival and treatment response were investigated, within the context of the inclusion and exclusion criteria of TOPAZ-1 and in correspondence with genetic alterations of the cancer., Results: In total, 35 patients, of which 51% met the inclusion criteria of the TOPAZ-1 trial, were analysed. Patients treated within TOPAZ-1 criteria did not have a significantly different median overall survival and progression free survival than the rest of the patients (10.3 versus 9.7 months and 5.3 versus 5 months, respectively). The disease control rate of patients within the TOPAZ-1 criteria was 61.1%, in comparison to 58.8% in the rest of patients. A total of 51 grade 3 and 4 adverse events were observed without significant differences in the subgroups. No specific correlating patterns of genetic alterations with survival and response were observed., Conclusions: The treatment of advanced patients with BTC with durvalumab and gem/cis, even beyond the inclusion criteria of the TOPAZ-1 trial, shows promising safety., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
44. Predicted vs. measured paraspinal muscle activity in adolescent idiopathic scoliosis patients: EMG validation of optimization-based musculoskeletal simulations.
- Author
-
Rauber C, Lüscher D, Poux L, Schori M, Deml MC, Hasler CC, Bassani T, Galbusera F, Büchler P, and Schmid S
- Subjects
- Child, Humans, Adolescent, Electromyography, Paraspinal Muscles diagnostic imaging, Spine, Scoliosis diagnostic imaging, Kyphosis
- Abstract
Musculoskeletal (MSK) models offer great potential for predicting the muscle forces required to inform more detailed simulations of vertebral endplate loading in adolescent idiopathic scoliosis (AIS). In this work, simulations based on static optimization were compared with in vivo measurements in two AIS patients to determine whether computational approaches alone are sufficient for accurate prediction of paraspinal muscle activity during functional activities. We used biplanar radiographs and marker-based motion capture, ground reaction force, and electromyography (EMG) data from two patients with mild and moderate thoracolumbar AIS (Cobb angles: 21° and 45°, respectively) during standing while holding two weights in front (reference position), walking, running, and object lifting. Using a fully automated approach, 3D spinal shape was extracted from the radiographs. Geometrically personalized OpenSim-based MSK models were created by deforming the spine of pre-scaled full-body models of children/adolescents. Simulations were performed using an experimentally controlled backward approach. Differences between model predictions and EMG measurements of paraspinal muscle activity (both expressed as a percentage of the reference position values) at three different locations around the scoliotic main curve were quantified by root mean square error (RMSE) and cross-correlation (XCorr). Predicted and measured muscle activity correlated best for mild AIS during object lifting (XCorr's ≥ 0.97), with relatively low RMSE values. For moderate AIS as well as the walking and running activities, agreement was lower, with XCorr reaching values of 0.51 and comparably high RMSE values. This study demonstrates that static optimization alone seems not appropriate for predicting muscle activity in AIS patients, particularly in those with more than mild deformations as well as when performing upright activities such as walking and running., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.
- Author
-
Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, Pizzato E, Birebent R, Mbogning Fonkou MD, Zoppi S, Reni A, Dalban C, Leduc M, Ferrere G, Durand S, Ly P, Silvin A, Mulder K, Dutertre CA, Ginhoux F, Yonekura S, Roberti MP, Tidjani-Alou M, Terrisse S, Chen J, Kepp O, Schippers A, Wagner N, Suárez-Gosálvez J, Kobold S, Fahrner JE, Richard C, Bosq J, Lordello L, Vitali G, Galleron N, Quinquis B, Le Chatelier E, Blanchard L, Girard JP, Jarry A, Gervois N, Godefroy E, Labarrière N, Koschny R, Daillère R, Besse B, Truntzer C, Ghiringhelli F, Coatnoan N, Mhanna V, Klatzmann D, Drubay D, Albiges L, Thomas AM, Segata N, Danlos FX, Marabelle A, Routy B, Derosa L, Kroemer G, and Zitvogel L
- Subjects
- Animals, Humans, Mice, Bacteria immunology, Cell Movement, Fecal Microbiota Transplantation, Interleukin-17 metabolism, Th17 Cells immunology, Gastrointestinal Tract immunology, Gastrointestinal Tract microbiology, Anti-Bacterial Agents adverse effects, Cell Adhesion Molecules metabolism, Drug Resistance, Neoplasm, Gastrointestinal Microbiome immunology, Immune Checkpoint Inhibitors therapeutic use, Immune Tolerance drug effects, Immunologic Surveillance, Integrins metabolism, Mucoproteins metabolism, Neoplasms immunology, Neoplasms therapy
- Abstract
Antibiotics (ABX) compromise the efficacy of programmed cell death protein 1 (PD-1) blockade in cancer patients, but the mechanisms underlying their immunosuppressive effects remain unknown. By inducing the down-regulation of mucosal addressin cell adhesion molecule 1 (MAdCAM-1) in the ileum, post-ABX gut recolonization by Enterocloster species drove the emigration of enterotropic α4β7
+ CD4+ regulatory T 17 cells into the tumor. These deleterious ABX effects were mimicked by oral gavage of Enterocloster species, by genetic deficiency, or by antibody-mediated neutralization of MAdCAM-1 and its receptor, α4β7 integrin. By contrast, fecal microbiota transplantation or interleukin-17A neutralization prevented ABX-induced immunosuppression. In independent lung, kidney, and bladder cancer patient cohorts, low serum levels of soluble MAdCAM-1 had a negative prognostic impact. Thus, the MAdCAM-1-α4β7 axis constitutes an actionable gut immune checkpoint in cancer immunosurveillance.- Published
- 2023
- Full Text
- View/download PDF
46. Impact of the ileal microbiota on colon cancer.
- Author
-
Roberti MP, Rauber C, Kroemer G, and Zitvogel L
- Subjects
- Humans, Ileum, Immune System, Microbiota, Gastrointestinal Microbiome, Colonic Neoplasms etiology, Colonic Neoplasms therapy
- Abstract
Besides tumor cell-intrinsic oncogenic pathways, host and environmental factors have a major impact on cancer immunosurveillance and the efficacy of immunotherapeutics. Several modalities of anticancer treatments including immunogenic chemotherapies and immune checkpoint inhibitors lose their efficacy in patients treated with broad-spectrum antibiotics, pointing to a key role for the gut microbiota. The complex interactions between intestinal microbes, gut immunity and anti-tumor responses constitute an emerging field of investigation. In this work, we revise key primary literature, with an emphasis on recent mechanistic insights, unraveling the interplay between the immunosurveillance of colon cancers and ileal factors including the local microbiota, tissue architecture and immune system., Competing Interests: Declaration of Competing Interest LZ and GK are cofounders of EverImmune, a biotech company devoted to the use of commensal bacteria for the treatment of cancers. MPR and LZ hold patent PCT/EP2018/079878 related to treatments and gut prognostic signatures in colorectal cancer., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
47. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer.
- Author
-
Terrisse S, Goubet AG, Ueda K, Thomas AM, Quiniou V, Thelemaque C, Dunsmore G, Clave E, Gamat-Huber M, Yonekura S, Ferrere G, Rauber C, Pham HP, Fahrner JE, Pizzato E, Ly P, Fidelle M, Mazzenga M, Costa Silva CA, Armanini F, Pinto F, Asnicar F, Daillère R, Derosa L, Richard C, Blanchard P, Routy B, Culine S, Opolon P, Silvin A, Ginhoux F, Toubert A, Segata N, McNeel DG, Fizazi K, Kroemer G, and Zitvogel L
- Subjects
- Androgen Antagonists pharmacology, Androgen Antagonists therapeutic use, Androgens therapeutic use, Animals, Humans, Immune System, Male, Mice, Gastrointestinal Microbiome, Prostatic Neoplasms, Castration-Resistant drug therapy
- Abstract
Background: Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant PC (CRPC). We investigated a mouse model of PC as well as specimens from PC patients to unravel an unsuspected contribution of thymus-derived T lymphocytes and the intestinal microbiota in the efficacy of ADT., Methods: Preclinical experiments were performed in PC-bearing mice, immunocompetent or immunodeficient. In parallel, we prospectively included 65 HSPC and CRPC patients (Oncobiotic trial) to analyze their feces and blood specimens., Results: In PC-bearing mice, ADT increased thymic cellularity and output. PC implanted in T lymphocyte-depleted or athymic mice responded less efficiently to ADT than in immunocompetent mice. Moreover, depletion of the intestinal microbiota by oral antibiotics reduced the efficacy of ADT. PC reduced the relative abundance of Akkermansia muciniphila in the gut, and this effect was reversed by ADT. Moreover, cohousing of PC-bearing mice with tumor-free mice or oral gavage with Akkermansia improved the efficacy of ADT. This appears to be applicable to PC patients because long-term ADT resulted in an increase of thymic output, as demonstrated by an increase in circulating recent thymic emigrant cells (sjTRECs). Moreover, as compared with HSPC controls, CRPC patients demonstrated a shift in their intestinal microbiota that significantly correlated with sjTRECs. While feces from healthy volunteers restored ADT efficacy, feces from PC patients failed to do so., Conclusions: These findings suggest the potential clinical utility of reversing intestinal dysbiosis and repairing acquired immune defects in PC patients., Competing Interests: Competing interests: LZ and GK are scientific cofounders of everImmune, a company that develops bacteria for the treatment of cancer. GK is a scientific cofounder of Samsara Therapeutics and Therafast Bio. Acknowledgments: LZ laboratory was supported by the Germano-French ANR Ileobiome—19-CE15-0029-01 and H2020 ONCOBIOME N°825410, RHU Torino Lumière ANR-16-RHUS-0008; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE). GK is supported by Agence Nationale de la Recherche (ANR)—Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association 'Ruban Rose'; Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); the Leducq Foundation; the and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001. AMT and EC are supported by the French Government’s Investissement d’Avenir Program, Laboratoire d’Excellence 'Milieu Intérieur' Grant ANR-10-LABX-69-01. INSERM U.1160 is a member of OPALE Carnot Institute, The Organization for Partnerships in Leukemia. MG-H and DGM are supported by the grant funding NIH/NCI P01 CA250927., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
48. Combining Structural with Functional Model Properties in Iron Synthetic Analogue Complexes for the Active Site in Rabbit Lipoxygenase.
- Author
-
Dobbelaar E, Rauber C, Bonck T, Kelm H, Schmitz M, de Waal Malefijt ME, Klein JEMN, and Krüger HJ
- Subjects
- Animals, Catalytic Domain, Iron Compounds chemical synthesis, Iron Compounds chemistry, Lipoxygenase chemistry, Molecular Structure, Rabbits, Iron Compounds metabolism, Lipoxygenase metabolism
- Abstract
Iron complexes that model the structural and functional properties of the active iron site in rabbit lipoxygenase are described. The ligand sphere of the mononuclear pseudo-octahedral cis -(carboxylato)(hydroxo)iron(III) complex, which is completed by a tetraazamacrocyclic ligand, reproduces the first coordination shell of the active site in the enzyme. In addition, two corresponding iron(II) complexes are presented that differ in the coordination of a water molecule. In their structural and electronic properties, both the (hydroxo)iron(III) and the (aqua)iron(II) complex reflect well the only two essential states found in the enzymatic mechanism of peroxidation of polyunsaturated fatty acids. Furthermore, the ferric complex is shown to undergo hydrogen atom abstraction reactions with O-H and C-H bonds of suitable substrates, and the bond dissociation free energy of the coordinated water ligand of the ferrous complex is determined to be 72.4 kcal·mol
-1 . Theoretical investigations of the reactivity support a concerted proton-coupled electron transfer mechanism in close analogy to the initial step in the enzymatic mechanism. The propensity of the (hydroxo)iron(III) complex to undergo H atom abstraction reactions is the basis for its catalytic function in the aerobic peroxidation of 2,4,6-tri( tert -butyl)phenol and its role as a radical initiator in the reaction of dihydroanthracene with oxygen.- Published
- 2021
- Full Text
- View/download PDF
49. Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients.
- Author
-
Picard M, Yonekura S, Slowicka K, Petta I, Rauber C, Routy B, Richard C, Iebba V, Tidjani Alou M, Becharef S, Ly P, Pizzato E, Lehmann CHK, Amon L, Klein C, Opolon P, Gomperts Boneca I, Scoazec JY, Hollebecque A, Malka D, Ghiringhelli F, Dudziak D, Berx G, Vereecke L, van Loo G, Kroemer G, Zitvogel L, and Roberti MP
- Subjects
- Animals, Humans, Mice, Prognosis, Colonic Neoplasms physiopathology, Ileal Diseases complications, Ileum pathology
- Abstract
Ileal epithelial cell apoptosis and the local microbiota modulate the effects of oxaliplatin against proximal colon cancer by modulating tumor immunosurveillance. Here, we identified an ileal immune profile associated with the prognosis of colon cancer and responses to chemotherapy. The whole immune ileal transcriptome was upregulated in poor-prognosis patients with proximal colon cancer, while the colonic immunity of healthy and neoplastic areas was downregulated (except for the Th17 fingerprint) in such patients. Similar observations were made across experimental models of implanted and spontaneous murine colon cancer, showing a relationship between carcinogenesis and ileal inflammation. Conversely, oxaliplatin-based chemotherapy could restore a favorable, attenuated ileal immune fingerprint in responders. These results suggest that chemotherapy inversely shapes the immune profile of the ileum-tumor axis, influencing clinical outcome.
- Published
- 2021
- Full Text
- View/download PDF
50. SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study.
- Author
-
Rauber C, Tiwari-Heckler S, Pfeiffenberger J, Mehrabi A, Lund F, Gath P, Mieth M, Merle U, and Rupp C
- Subjects
- Adult, Antibodies, Viral blood, COVID-19 immunology, Female, Germany epidemiology, Humans, Immunoglobulin G blood, Immunoglobulin G immunology, Male, Middle Aged, Postoperative Complications immunology, Prospective Studies, RNA, Viral blood, Risk Factors, Seroconversion, Seroepidemiologic Studies, COVID-19 epidemiology, Liver Transplantation adverse effects, Postoperative Complications epidemiology, SARS-CoV-2 immunology
- Abstract
Background: In liver transplant (LT) recipients with severe coronavirus disease 2019 (COVID-19), fatal outcome has been reported in a substantial subset of patients. Whether LT recipients are at increased risk for severe COVID-19 compared with the general population is controversial. Here we report the results of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in a large LT recipient cohort., Methods: A total of 219 LT recipients were enrolled between May 5, 2020, and August 6, 2020, at the University Hospital Heidelberg. Serum blood samples were collected and tested for anti-SARS-CoV-2 IgG. SARS-CoV-2 RNA was detected in nasopharyngeal swabs using reverse transcription-polymerase chain reaction assays., Results: Taking into account known risk factors of arterial hypertension, obesity, diabetes, or leukopenia, LT recipients a priori represented a high-risk cohort for severe COVID-19 with 101 of 219 (46.1%) presenting with more than 2 risk factors for severe COVID-19. Out of 219 LT recipients, 8 (3.7%) either had a positive test result for nasopharyngeal SARS-CoV-2 RNA or anti-SARS-CoV-2 serum IgG. Five of eight (62.5%) did not show any clinical signs of infection, three of eight (37.5%) had self-limited disease, and none required hospitalization for COVID-19. Two of eight (25%) had known exposure to infected health care staff as the probable source of infection., Conclusions: In summary, LT recipients showed a SARS-CoV-2 seroconversion rate similar to that of the general population with a substantial percentage of unrecognized infections., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.